Investment Analysts’ Recent Ratings Updates for Regeneron Pharmaceuticals (REGN)

Several analysts have recently updated their ratings and price targets for Regeneron Pharmaceuticals (NASDAQ: REGN):

• 4/30/2024 – Regeneron Pharmaceuticals was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.
• 4/24/2024 – Regeneron Pharmaceuticals had its price target raised by analysts at TD Cowen from $1,020.00 to $1,030.00. They now have a “buy” rating on the stock.
• 4/20/2024 – Regeneron Pharmaceuticals was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.
• 4/17/2024 – Regeneron Pharmaceuticals had its price target raised by analysts at UBS Group AG from $1,090.00 to $1,099.00. They now have a “buy” rating on the stock.
• 4/15/2024 – Regeneron Pharmaceuticals had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $925.00 price target on the stock.
• 4/12/2024 – Regeneron Pharmaceuticals had its price target raised by analysts at Bank of America Co. from $710.00 to $720.00. They now have an “underperform” rating on the stock.
• 4/12/2024 – Regeneron Pharmaceuticals was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.
• 4/9/2024 – Regeneron Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $1,189.00 price target on the stock.
• 4/3/2024 – Regeneron Pharmaceuticals had its “buy” rating reaffirmed by analysts at Truist Financial Co.. They now have a $1,135.00 price target on the stock.
• 3/26/2024 – Regeneron Pharmaceuticals had its “buy” rating reaffirmed by analysts at Truist Financial Co.. They now have a $1,135.00 price target on the stock.
• 3/13/2024 – Regeneron Pharmaceuticals had its price target raised by analysts at Morgan Stanley from $1,104.00 to $1,115.00. They now have an “overweight” rating on the stock.
• 3/12/2024 – Regeneron Pharmaceuticals is now covered by analysts at Sanford C. Bernstein. They set an “outperform” rating and a $1,125.00 price target on the stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $903.48 on Thursday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $684.80 and a twelve month high of $998.33. The company’s 50 day moving average is $944.78 and its 200 day moving average is $895.25. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. The company has a market cap of $99.17 billion, a PE ratio of 26.00, a price-to-earnings-growth ratio of 2.56 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. During the same quarter in the prior year, the company earned $10.96 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up .6% on a year-over-year basis. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.86 EPS for the current year.

Insider Buying and Selling

In related news, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the transaction, the executive vice president now owns 13,789 shares in the company, valued at approximately $12,888,716.19. The sale was disclosed in a filing with the SEC, which is available through this link. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the sale, the executive vice president now owns 13,789 shares in the company, valued at approximately $12,888,716.19. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $982.05, for a total value of $98,205.00. Following the completion of the sale, the director now owns 18,282 shares in the company, valued at approximately $17,953,838.10. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,095 shares of company stock worth $9,664,476. 8.83% of the stock is owned by company insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Meyer Handelman Co. boosted its position in Regeneron Pharmaceuticals by 11.4% in the 3rd quarter. Meyer Handelman Co. now owns 4,235 shares of the biopharmaceutical company’s stock worth $3,485,000 after purchasing an additional 435 shares in the last quarter. Stifel Financial Corp lifted its position in shares of Regeneron Pharmaceuticals by 12.2% during the 3rd quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock valued at $25,537,000 after buying an additional 3,385 shares in the last quarter. LPL Financial LLC lifted its position in shares of Regeneron Pharmaceuticals by 9.3% during the 3rd quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock valued at $33,522,000 after buying an additional 3,479 shares in the last quarter. Exchange Traded Concepts LLC lifted its position in shares of Regeneron Pharmaceuticals by 32.7% during the 4th quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock valued at $4,351,000 after buying an additional 1,221 shares in the last quarter. Finally, Monetary Management Group Inc. lifted its position in shares of Regeneron Pharmaceuticals by 4.8% during the 3rd quarter. Monetary Management Group Inc. now owns 1,095 shares of the biopharmaceutical company’s stock valued at $901,000 after buying an additional 50 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.